Immune-Based Therapeutics for Neurological Disease

 Friday, May 6, 2022     2:00 PM – 4:00 PM ET     Room B113–116

Immune-Based Therapeutics for Neurological Disease

Chairs

• Giorgio Raimondi, Johns Hopkins Univ. Sch. of Med.
• Andrea Castillo, Eastern Washington Univ.

Speakers

• Md Jahirul Islam, Seoul Natl. Univ. Col. of Med., Non-classical anti-inflammatory drugs (NCAIDs) ameliorates brain inflammation and improves memory in Alzheimer’s diseases mice model
• Jörg Wischhusen, Univ. Hosp. Wuerzburg, Alpha-synuclein peptides presented on chimeric MHC class Ib molecules prevent loss of substantia nigra neurons in an animal model for Parkinson’s disease
• Kevin G. Senior, Univ. of Florida Col. of Med., Novel gene immunotherapy prevents Aquaporin-4 (AQP4) mediated neuroinflammation and demyelination in a mouse model of multiple sclerosis
• Weikan Wang, Univ. of North Texas Hlth. Sci. Ctr., Aging impairs regulatory T cell (Treg) cells to affect late-onset (aged) multiple sclerosis (MS) – with the model of experimental autoimmune encephalomyelitis (EAE)
• Daniel Hwang, Thomas Jefferson Univ., CSF-1 maintains pathogenic but not homeostatic myeloid cells in the central nervous system during autoimmune neuroinflammation
• Javier Ochoa-Reparaz, Eastern Washington Univ., A GABA-producing probiotic for the protection of CNS demyelinating inflammation
• Gaurav Kumar, Oklahoma Med. Res. Fndn., Deficiency in B Cell Maturation Antigen reveals sex differences in Experimental Autoimmune Encephalomyelitis
• Giorgio Raimondi, Johns Hopkins Univ. Sch. of Med., Tolerogenic Artificial Antigen Presenting Cells for Selective Tolerance in Autoimmune Disease